- | Tessera Therapeutics
In humanized mouse models, Tessera is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease
CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company’s gene writing platform and programs more broadly.
- | Aphaia Pharma
Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies
Aphaia Pharma, a Swiss biotech, is developing an oral glucose formulation. This aims to restore endogenous signaling mechanisms and metabolic homeostasis in people with obesity, with the goal of mimicking the metabolic effects of bypass surgery without the adverse effects. Its lead drug candidate is currently in a Phase II proof-of-concept study in individuals with obesity, and another Phase II in people with pre-diabetes.
- | Anima Biotech
New Apps For AI in mRNA With Anima Biotech’s Yochi Slonim
From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired by Siemens. Those big deals that came on the heels of several other Yochi Slonim software startups. But Slonim’s not in software development anymore.
- | Aphaia Pharma
Biotechs face upward battle with recruiting patients on obesity trials
Following plans to add cohorts in an ongoing Phase II weight-loss study, Aphaia Pharma’s CSO Steffen-Sebastian Bolz says there are now rising challenges with the recruitment of patients in obesity trials.
- | eFFECTOR
Selective Translation Regulator Inhibitors: Depriving cancer of what it needs
In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.
- | Claris Bio
Claris Bio’s journey toward treating neurotrophic keratitis
So with positive data, and in the summer, we would begin another pivotal trial. This trial will be slightly different in that it will be slightly larger and will include both the US and European sites.
- | Skye Bioscience
Obesity drugmaker lands first biopharma uplisting onto Nasdaq since last summer
But behind the industry’s first uplisting of 2024, from San Diego biotech Skye Bioscience, is investors’ interest in an area of drug R&D that every therapeutics developer wants in on right now: the next wave of obesity medications.
- | Elicio Therapeutics
How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics
Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body’s immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.
